Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In part 1 NHVs will receive a single dose of ARO-MUC5AC or placebo. In part 2 of the study, NHVs, adult patients with asthma, and adult patients with COPD will receive 3 doses of ARO-MUC5AC or placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: additional inclusion/exclusion criteria may apply per protocol
Primary purpose
Allocation
Interventional model
Masking
104 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Medical Monitor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal